Midi Health Review: In-Network Insurance Plus a Published Price for Every Single Dose

What Is Midi Health?

Midi Health is a virtual care clinic built for women in midlife. Weight is one of nine care areas it covers, alongside menopause, perimenopause, longevity, sexual wellness, mood and memory, hair and skin, sleep, and cancer survivorship. It describes its weight offering as 'hormone-first weight care built for women.'

That framing matters clinically. Weight gain in perimenopause and menopause has hormonal drivers that a general-purpose GLP-1 seller is not set up to address, and Midi is one of very few providers that can prescribe a GLP-1 and hormone therapy from the same clinician, in the same care plan.

Commercially, Midi is structured like an actual medical practice rather than a subscription box. Visits are billed to insurance — Midi states it is in-network with most PPO plans nationwide — and medication is sold separately at published prices with no membership fee layered on top. Its own summary is blunt: 'No membership fees. You only pay for your care and your medications.'

The pricing page is the most granular we have encountered anywhere in this market. Midi publishes a price for every individual dose across four formulations — injectable GLP-1, injectable dual GLP-1/GIP, sublingual GLP-1, and sublingual dual GLP-1/GIP — with shipping and supplies included in every figure.

Medications Offered & Pricing

Every published price is for a 4-week supply and includes shipping and supplies. Midi states: 'All compounded GLP-1s and GLP-1/GIPs from Midi Health include shipping and supplies in the prices you see — everything you need.' Midi also prescribes brand-name GLP-1s, which are sent to your pharmacy of choice rather than shipped by Midi. The company notes that medications are prescribed by licensed clinicians when appropriate, that not everyone is a candidate, and that dosages and pricing are subject to availability.

Brand-Name or Compounded?

Midi offers both. Its compounded line covers injectable and sublingual GLP-1 and dual GLP-1/GIP formulations at the published prices above. It also prescribes brand-name GLP-1s, which go to your pharmacy of choice rather than shipping from Midi.

On the compounded side, Midi makes a disclosure that very few competitors match: 'Our partner compounding pharmacies are licensed and 503B-accredited.' The 503B distinction is meaningful — 503B outsourcing facilities register with the FDA, are subject to FDA inspection, and follow more manufacturer-like quality standards than 503A pharmacies compounding against individual prescriptions.

That said, compounded semaglutide and tirzepatide remain not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not generic versions of Ozempic, Wegovy, Mounjaro or Zepbound. A 503B source raises the quality floor; it does not change the regulatory status.

The Consultation Process

Eligibility

• •Midi is built for women in midlife — its care model centres on perimenopause, menopause and related concerns.
• •Medications are prescribed by licensed clinicians when appropriate; Midi states plainly that 'Not everyone is a candidate.'
• •Midi is in-network with most PPO plans nationwide, with a state-by-state coverage checker available before you book.
• •Midi cannot treat Medicaid or Medi-Cal patients — it states it is not enrolled with state healthcare programs and cannot see these patients even on a self-pay basis.
• •Midi is not covered by Medicare or any Medicare-related plan. Medicare beneficiaries can be seen as self-pay patients but cannot submit any claims for visits, medications or associated services.
• •A specific published BMI threshold is not disclosed.

Provider Involvement, Labs & Pharmacy

Shipping & Support Services

Included in every published medication price. Midi states all prices include shipping and supplies, and that medication ships discreetly. Brand-name prescriptions are instead sent to your pharmacy of choice.

• •Insurance-billed visits with most PPO plans, nationwide
• •State-by-state coverage checker and employer coverage lookup
• •Public 'Meet Our Clinicians' page
• •'Message Your Clinician' channel for ongoing questions
• •Care Plans spanning nine care areas, not just weight
• •Shipping and supplies included in all medication prices
• •Both compounded and brand-name GLP-1 routes
• •Employer and health-system partnership channels
• •Email support at support@joinmidi.com

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Midi Health May Be Best For

• •Women in perimenopause or menopause whose weight concerns have hormonal drivers
• •Anyone with a PPO plan who wants insurance to actually pay for the visits
• •Patients who want to know the exact price at every dose before starting
• •People who want a GLP-1 and hormone therapy managed by one clinician in one plan
• •Patients who want a needle-free sublingual option including dual-action GLP-1/GIP
• •Anyone who wants 503B-sourced compounded medication rather than an unnamed pharmacy

Limitations

• •The insurance exclusions are significant and unusually far-reaching. Midi cannot treat Medicaid or Medi-Cal patients even if they offer to pay cash, and Medicare beneficiaries can be seen only as self-pay with no ability to claim anything back. That rules out a large share of the population outright.
• •Self-pay economics are poor. At $250 for an initial visit and $150 for follow-ups on top of medication, a patient without PPO coverage will find Midi expensive compared with flat-rate compounded providers.
• •The published dose ladder is honest but shows real escalation: dual-action injectable runs from $210 to $434 per four weeks, roughly doubling as you titrate.
• •Midi's model only makes sense if you are its target patient. For men, younger women, or anyone wanting a simple low-cost compounded subscription, this is the wrong clinic.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Midi Health is the best-disclosed provider in this entire roundup, and it is not close. It publishes a price for every individual dose across four formulations. It includes shipping and supplies in each figure. It charges no membership fee. It states that its compounding pharmacies are 503B-accredited. It names its clinicians. It offers a coverage checker before you book. And it tells you plainly which patients it cannot serve — a disclosure most companies would bury.

The insurance position is what really separates it. Nearly every 'insurance' program in this market sells you navigation: someone to argue with your insurer on your behalf while you pay a membership fee. Midi is in-network. You book a visit, your PPO covers it, you pay a copay. That is an ordinary medical relationship, and it is startlingly rare here.

The hormone-first framing is also more than marketing. Weight gain in perimenopause has causes a generic GLP-1 vendor cannot address, and having one clinician manage a GLP-1 and hormone therapy in a single Care Plan is a real clinical advantage for the patient Midi is built for.

The caveats are about fit, not quality. If you have Medicaid, Medi-Cal or Medicare, Midi is largely closed to you. Without PPO coverage, $250 and $150 visit fees make it expensive. High doses reach $434 per four weeks. And if you are not a woman in midlife, this is simply not your clinic. But for the patient it was designed for, with the coverage it works with, Midi is the standard the rest of this market should be measured against.